The State Street SPDR S&P Biotech ETF (XBI) has risen 58% over the past year and is currently trading around $128, with potential for nearly 50 points of upside to reach its 2021 all‑time high of $175.

It tracks the S&P Biotechnology Select Industry Index and equally weights 145 biotech stocks, giving stronger exposure to smaller companies that benefit from FDA approvals, M&A announcements, and other breakthroughs. Top holdings include Moderna (2.25%), Roivant Sciences (1.74%), Amgen (1.50%), and others such as Vacxyte, Inc. (1.73%), Arcellx, Inc. (1.66%), Revolution Medicines, Inc. (1.59%), Praxis Precision Medicines, Inc. (1.57%), Gilead Sciences, Inc. (1.49%), Amicus Therapeutics, Inc. (1.48%), and Miriam Pharmaceuticals, Inc. (1.41%).

The fund has $8.06 billion in net assets, an average daily volume of 10 million shares, and an expense ratio of 0.35%. Its yield is 0.35%, YTD return 4.76%, 52‑week range $66.66–$132.09, 1‑year trailing return 44.10%, beta 1.47, 3‑year return 15.60%, and 5‑year return ‑2.83%. The P/E ratio is N/A, while the 10‑year return stands at 10.43%.

ETF Statistics Table

The recent market environment has been volatile. After hitting a peak of $175 in January 2021, XBI fell over 50% to $63 in 2023, then recovered to $104, plummeted to $66 in April 2025 following President Trump’s tariff announcements, and has since climbed back to the $128 region. This still leaves roughly 45 points of upside before hitting technical resistance at the 2021 all‑time high.

Biotech analysts such as Goldman Sachs’ Salveen Richter and Mizuho’s Jared Holz are bullish on the sector for 2026, citing three key drivers:

1. Interest Rate Cuts – With the Federal Reserve’s term ending in May, the likelihood of a long‑overdue rate cut is increasing, which would lower financing costs for clinical trials.
2. Mergers & Acquisitions – Lower borrowing costs are expected to boost biotech M&A activity by 15%+ in 2026, as major pharma firms like Eli Lilly, GSK, and Gilead hunt for pipeline replacements in oncology, metabolic disorders, radiopharmaceuticals, and immunology.
3. Artificial Intelligence – AI can compress a decade‑long drug‑discovery cycle into just 2–3 years, dramatically accelerating R&D timelines.

XBI’s composition further enhances its appeal: by equally weighting its holdings, the ETF gives smaller, high‑growth companies a larger footprint, allowing investors to capture surges from breakthroughs or regulatory approvals that market‑cap‑weighted funds might miss. TipRanks reports a 55% “strong buy” consensus for XBI.

Notably, XBI’s exposure to COVID‑19 vaccine manufacturers is minimal, reducing concerns about liability from recent disclosures of miscarriages, cancers, and myocarditis linked to those vaccines.

The upside potential remains substantial; analysts believe that reaching the $175 level is achievable, representing nearly 50 points of upside from the current $128 price.

Analyst Viewpoint 以我多年的市場經驗來看，XBI 的潛力正當中國生技公司加速創新、美國政策 supportive、以及 AI 研發加速的背景下，具備相當的買入理由。若不動用資金做投資，我個人建議在回調至 $110 以下時逐步進場，以捕捉 forthcoming 上漲行情。